<DOC>
	<DOCNO>NCT00326872</DOCNO>
	<brief_summary>This phase II trial study well AZD2171 work treat patient neurofibromatosis type 1 plexiform neurofibroma and/or neurofibroma near spine . AZD2171 may stop growth tumor cell block enzymes need cell growth block blood flow tumor .</brief_summary>
	<brief_title>AZD2171 Treating Patients With Neurofibromatosis Type 1 Plexiform Neurofibroma and/or Neurofibroma Near Spine</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess efficacy AZD2171 , term volume change target tumor 3-dimensional magnetic resonance imaging ( 3D MRI ) . II . Describe define toxicity AZD2171 patient . SECONDARY OBJECTIVES : I. Assess value 3D MRI data analysis evaluate plexiform paraspinal neurofibroma compare conventional 2-dimensional MRI data analysis . II . Assess value delay contrast-enhanced MRI ( DCE-MRI ) determine change vascularity neurofibromas treatment . III . Assess quality life patient treat AZD2171 . IV . Evaluate effect AZD2171 biological change human neurofibroma compare pre- post-treatment specimen patient involve trial , alternatively , evaluate effect AZD2171 human tumor graft experimental animal . V. Evaluate relevant pharmacodynamic marker ( circulate endothelial cell [ CECs ] vascular endothelial growth factor-2 [ VEGF2 ] level ) pharmacogenetics analysis ( variation kdr/flk-1 gene ) response AZD2171 . OUTLINE : This multicenter study . Patients stratify accord tumor location ( peripheral v paraspinal plexiform neurofibroma ) . Patients receive oral AZD2171 daily day 1-28 . Treatment repeat every 28 day 26 course absence disease progression unacceptable toxicity . Patients respond stable disease may continue treatment beyond 26 course absence disease progression unacceptable toxicity . Quality life assess baseline , prior course 2 , prior course 4 , every 6 course thereafter .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Diagnosis* neurofibromatosis type 1 ( NF1 ) extensive plexiform and/or paraspinal neurofibromasproducing pain ( control use overthecounter medication ) , progressive neurologic deficit , significant neurologic consequenceswith continuous tumor growth Extensive paraspinal neurofibroma define neurofibroma involves multiple neural root ≥ 3 spinal level connection level extend laterally along nerve Symptomatic neurofibroma &lt; 3 spinal level , surgical treatment possible , allow Meets ≥ 2 diagnostic criterion NF1 , include follow : Six caféaulait spot ( ≥ 1.5 cm postpubertal patient ) Freckling axilla groin Optic glioma Two Lisch nodule Distinctive bony lesion ( dysplasia sphenoid bone dysplasia orthinning longbone cortex ) Firstdegree relative NF1 Patients document mutation neurofibromin gene onlysymptomatic plexiform and/or paraspinal neurofibroma fulfill clinical criterion eligible Measurable disease , define ≥ 1 lesion whose long diameter beaccurately measure 8.0 cm^3 3dimensional ( 3D ) MRI Skin lesion consideredmeasurable ( e.g. , plexiform neurofibroma ) , MRI image still require 3D measurement Patients symptomatic neurofibroma , surgery feasible , refuse surgery goodsurgical candidate due high risk damage vital structure spinal cordinjury eligible No evidence progressive optic glioma , malignant glioma , malignant peripheralnerve sheath tumor , cancer require treatment chemotherapy orradiotherapy ECOG performance status 03 WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Bilirubin normal ( patient Gilbert 's syndrome allow despite elevated bilirubin ) Alkaline phosphatase normal AST ALT ≤ 2.5 time upper limit normal Thyroidstimulating hormone free thyroxin normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Ejection fraction ≥ 50 % echocardiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled , serious medical condition would preclude study participation , include follow : Cardiac arrhythmia Diabetes Serious infection Significant cardiac , pulmonary , hepatic , organ dysfunction No psychiatric illness social situation would preclude study compliance No history allergic reaction attribute compound similar chemical orbiologic composition AZD2171 No New York Heart Association class III IV disease Class II disease control treatment increase monitoring allow No systolic blood pressure ( BP ) &gt; 130 mm Hg diastolic BP &gt; 90 mm Hg No history familial long QT syndrome Mean QTc ≤ 470 msec ( Bazett 's correction ) EKG QTc prolongation ≤ 500 msec No significant ECG abnormality within past 14 day See Disease Characteristics More 30 day since prior investigational agent More 4 week since prior radiotherapy , chemotherapy , hormonal therapy direct thetumor , immunotherapy , biologic therapy ( e.g. , interferon ) , majorsurgery No concurrent medication may markedly affect renal function ( e.g. , vancomycin , amphotericin , pentamidine ) No concurrent CYP interactive medication No concurrent combination antiretroviral therapy HIVpositive patient No concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin , carbamazepine , phenobarbital ) No concurrent use drug biologics proarrhythmic potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>